“…These modulations can be based on quantitative alterations (Haywood and McKhann, 1971; Ting and Herberman, 1971; De Baetselier et al, 1983), specific to one gene product (De Baetselier et al, 1980;Schmidt and Festenstein, 1982) (Katzav, 1983). Previous studies indicated that gene products of the K and D ends might manifest different immunogenic properties (Wernet and Lilly, 1975;Miller et al, 1978;Hasek and Chutna, 1979). Furthermore Schmidt and Festenstein (1982) demonstrated that the absence from tumor cells of K-end expression reduces the immunogenic effect of tumor cells and their susceptibility to syngeneic CTL.…”